Overview of treatment success with short, long, and BPaL/M regimens in patients with drug resistant tuberculosis
DOI: https://doi.org/10.56922/quilt.v6i1.2220
BPaL/M Regimen Drug-Resistant Tuberculosis Long-Term Regimen Short-Term Regimen Treatment Success
Abstract
Background: Drug-resistant tuberculosis (DR-TB) remains a major challenge in global TB control efforts, particularly in middle-income countries such as Indonesia. Long-term regimens lasting 18–24 months have been associated with low treatment success rates due to their prolonged duration and high incidence of adverse drug reactions. More recent developments, namely the bedaquiline–pretomanid–linezolid regimen with or without moxifloxacin (BPaL/M), have demonstrated treatment success rates of up to 89–90% in international clinical trials.
Purpose: To describe the treatment success of short-term, long-term, and BPaL/M regimens among patients with drug-resistant tuberculosis.
Method: A retrospective descriptive study was conducted using medical record data of DR-TB patients who received long-term, short-term, or BPaL/M regimens during 2023–2024. Treatment outcome classification followed the WHO 2022 guidelines. The variables collected included patient characteristics, type of regimen, and treatment outcomes based on WHO standards: cured, treatment completed, treatment failed, lost to follow-up, and died.
Results: Of the 148 DR-TB patients who met the inclusion criteria, 98 patients (66.2%) received long-term regimens, 17 patients (11.5%) received short-term regimens, and 33 patients (22.3%) were treated with the BPaL/M regimen. The treatment success rate (cured + treatment completed) for the short-term regimen was 76.5%, which was lower compared to the long-term regimen at 83.7%. The BPaL/M regimen demonstrated the highest treatment success rate at 87.9%.
Conclusion: The treatment success rates for DR-TB patients at Dr. H. Abdul Moeloek Hospital indicate that the BPaL/M regimen provides the most favorable outcomes compared to long-term and short-term regimens.
Keywords: BPaL/M Regimen; Drug-Resistant Tuberculosis; Long-Term Regimen; Short-Term Regimen; Treatment Success.
Downloads
References
Ahmad, N., Ahuja, S.D., Akkerman, O.W., Alffenaar, J.W., Anderson, L.F., & Baghaei, P. (2018). Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: An individual patient data meta-analysis, The Lancet, 392(10150), pp. 821–834.
Conradie, F., Diacon, A.H., Ngubane, N., Howell, P., Everitt, D., & Crook, A.M. (2020). Treatment of highly drug-resistant pulmonary tuberculosis, New England Journal of Medicine, 382(10), pp. 893–902.
Dalton, T., Cegielski, P., Akksilp, S., Asencios, L., Campos Caoili, J., & Cho, S.N. (2017). Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: A prospective cohort study, The Lancet, 385(9984), pp. 1738–1747.
Du Cros, P., Khamraev, A., Tigay, Z. & Cooke, G.S. (2021). Adverse events and treatment interruptions among MDR-TB patients treated with longer regimens: A cohort study, International Journal of Tuberculosis and Lung Disease, 25(2), pp. 120–128.
Elisa, M., Setiabudi, D. & Dwiyana, R. F. (2023) Tuberculosis drug resistance mechanisms and implications for treatment, Journal of Infectious Disease Research, 12(1), pp. 55–63.
Ministry of Health Republic of Indonesia. (2023). Petunjuk teknis pengobatan tuberkulosis resisten obat. Jakarta: Kemenkes RI. Diakses dari: https://repository.kemkes.go.id/book/1284
Meressa, D., Hurtado, R.M., Andrews, J.R., Diro, E., Abato, K., Daniel, T. (2015). Achieving high treatment success for multidrug-resistant TB in Africa: Initiation and scale-up of MDR-TB care in Ethiopia, PLOS ONE, 10(4), e0123637.
Pontali, E., D’Ambrosio, L., Centis, R., Sotgiu, G. & Migliori, G.B. (2019). Multidrug-resistant tuberculosis and beyond: Improving treatment outcomes and reducing mortality, European Respiratory Review, 28(152), pp. 190–200.
Singh, R., Dwivedi, S.P., Gaharwar, U.S., Meena, R., Rajamani, P. & Prasad, T. (2020). Recent updates on drug-resistant tuberculosis: A review, Journal of Applied Pharmaceutical Science, 10(7), pp. 100–112.
Torrea, G., Martinez, E. & Carvalho, A.C. (2021). Adherence and barriers in the treatment of multidrug-resistant tuberculosis: Global evidence and programmatic implications, Journal of Global Health, 11(1), 04011.
Vanino, E., Battagin, T., Fregonese, F. & Dara, M. (2023). Drug-resistant tuberculosis: Challenges and programmatic responses in high-burden countries, International Journal of Infectious Diseases, 128, pp. 36–45.
World Health Organization (2020) WHO consolidated guidelines on drug-resistant tuberculosis treatment. Geneva: World Health Organization. Diakses dari: https://www.who.int/publications/i/item/9789241550529
World Health Organization. (2023). Global tuberculosis report 2023. Geneva: World Health Organization. Diakses dari: https://www.who.int/teams/global-programme-on-tuberculosis-and-lung-health/tb-reports/global-tuberculosis-report-2023
World Health Organization. (2022). WHO operational handbook on tuberculosis: Module 4—Drug-resistant TB treatment. Geneva: WHO. Diakses dari: https://www.who.int/publications/i/item/9789240065116
World Health Organization. (2023). Global tuberculosis report 2023. Geneva: WHO. Retreat from: https://www.who.int/teams/global-programme-on-tuberculosis-and-lung-health/tb-reports/global-tuberculosis-report-2023
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Artika Ananda Putri Nasution, Tri Umiana Soleha, Anisa Nuraisa Jausal, Achmad Gozali
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
